Skip to main content
    R

    Recursion Pharmaceuticals Inc (RXRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.90
    -0.28 (-8.79%)

    Market Cap: $1.99B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Recursion Pharmaceuticals Inc (RXRX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Recursion Pharmaceuticals are Sarepta Therapeutics (SRPT), Rapport Therapeutics, Inc. Common Stock (RAPP) and Replimune Group (REPL). By market cap, Recursion Pharmaceuticals ranks 5th of the 13 companies on this page; Beam Therapeutics (BEAM) is the largest at $2.36B.

    Peer Comparison

    RXRX's ROIC of -51.8% is above the peer median of -65.4%, and its revenue growth of 258.5% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Recursion Pharmaceuticals (RXRX)$1.99BN/A23.1x0.0%-51.8%258.5%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Rapport Therapeutics, Inc. Common Stock (RAPP)$1.55BN/A59.3x0.0%N/A0.0%0.00%
    Replimune Group Inc (REPL)$2.08BN/AN/A0.0%-65.4%0.0%0.00%
    Septerna, Inc. Common Stock (SEPN)$2.03BN/A20.3x-61.3%N/A-12.2%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Trevi Therapeutics Inc (TRVI)$1.95BN/AN/A0.0%N/A0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Inhibrx Biosciences, Inc. (INBX)$1.23BN/A610.4x0.0%-66.0%-100.0%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    Peer median$1.71B6.4x15.0x0.0%-65.4%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Recursion Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Rapport Therapeutics, Inc. Common Stock (RAPP)
    Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases...
    RAPP competitors
    Replimune Group Inc (REPL)
    Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
    REPL competitors
    Septerna, Inc. Common Stock (SEPN)
    Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform.
    SEPN competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors
    Trevi Therapeutics Inc (TRVI)
    Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious...
    TRVI competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Inhibrx Biosciences, Inc. (INBX)
    Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates.
    INBX competitors
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors

    Frequently Asked Questions About RXRX

    Who are Recursion Pharmaceuticals' main competitors?

    The companies most similar to Recursion Pharmaceuticals include Sarepta Therapeutics (SRPT), Rapport Therapeutics, Inc. Common Stock (RAPP), Replimune Group (REPL), Septerna, Inc. Common Stock (SEPN) and Vir Biotechnology (VIR), listed from the closest match.

    Who is Recursion Pharmaceuticals' biggest competitor?

    Beam Therapeutics (BEAM) is the largest of the similar companies at $2.36B; Sarepta Therapeutics (SRPT) is the closest match by business profile, size, sector and industry.

    How does RXRX stock compare with its competitors?

    RXRX's P/S is 23.1x against a peer median of 15.0x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Recursion Pharmaceuticals' competitors pays a higher dividend?

    Recursion Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Recursion Pharmaceuticals bigger than its competitors?

    No. Recursion Pharmaceuticals is 5th by market cap among the 13 companies on this page; the largest is Beam Therapeutics (BEAM) at $2.36B.